BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8983270)

  • 21. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
    Wang Y; Gonzalez M; Cheng C; Haouala A; Krueger T; Peters S; Decosterd LA; van den Bergh H; Perentes JY; Ris HB; Letovanec I; Debefve E
    Lasers Surg Med; 2012 Apr; 44(4):318-24. PubMed ID: 22362489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
    Piccart-Gebhart MJ; Bruning P; Gamucci T; Klijn J; Roy JA; Awada A; Kusenda Z; Van Vreckem A; Paridaens R
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):11-5. PubMed ID: 8893893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preoperative intra-arterial chemotherapy with THP-ADR for locally advanced breast cancer].
    Mukai S; Fujisaki T; Sato N
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1542-5. PubMed ID: 7574754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
    Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S
    J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
    Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
    Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxorubicin-induced cardiomyopathy.
    Swain SM
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
    [No Abstract]   [Full Text] [Related]  

  • 28. Adriamycin cardiac toxicity: a different hypothesis.
    Byfield JE
    Cancer Treat Rep; 1977; 61(3):497-8. PubMed ID: 872149
    [No Abstract]   [Full Text] [Related]  

  • 29. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
    Minisini AM; Andreetta C; Fasola G; Puglisi F
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American symposium looks at new antineoplastic drug.
    Korcok M
    Can Med Assoc J; 1985 Jul; 133(1):66-7. PubMed ID: 3891062
    [No Abstract]   [Full Text] [Related]  

  • 33. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
    Gabra H; Cameron DA; Lee LE; Mackay J; Leonard RC
    Br J Cancer; 1996 Dec; 74(12):2008-12. PubMed ID: 8980405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases].
    Fogarassy G; Fogarassyné Vathy Á; Kováts T; Hornyák L; Kenessey I; Veress G; Polgár C; Forster T
    Orv Hetil; 2020 Jun; 161(26):1094-1102. PubMed ID: 32541088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal doxorubicin.
    Wilkinson K
    Clin J Oncol Nurs; 2002; 6(1):59-61. PubMed ID: 11842492
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
    Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.